Published in Mol Brain on September 18, 2015
miR-24-3p Suppresses Malignant Behavior of Lacrimal Adenoid Cystic Carcinoma by Targeting PRKCH to Regulate p53/p21 Pathway. PLoS One (2016) 0.77
Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons. J Neuroinflammation (2016) 0.75
Correction to: Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21(WAF1/CIP1) expression. Mol Brain (2017) 0.75
Biosynthesis and genetic encoding of phosphothreonine through parallel selection and deep sequencing. Nat Methods (2017) 0.75
11a-N-Tosyl-5-deoxi-pterocarpan, LQB-223, a novel compound with potent antineoplastic activity toward breast cancer cells with different phenotypes. J Cancer Res Clin Oncol (2016) 0.75
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99
A more efficient method to generate integration-free human iPS cells. Nat Methods (2011) 7.39
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A (2005) 6.98
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis (2006) 5.96
Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci (2006) 5.32
Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet (2007) 4.99
The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron (2006) 4.51
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med (2010) 4.45
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J (2007) 3.89
Determination of the specific substrate sequence motifs of protein kinase C isozymes. J Biol Chem (1997) 3.86
Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem (2008) 3.86
Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J (2008) 3.51
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol (2011) 2.91
Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease. Cell (2014) 2.63
p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med (2010) 2.54
LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron (2012) 2.49
Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene (1999) 2.43
Recent advances in the genetics of Parkinson's disease. Annu Rev Genomics Hum Genet (2011) 2.29
LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res (2008) 2.09
A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology (2005) 2.00
Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration? J Neurochem (2009) 1.91
Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci (2013) 1.88
Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc Natl Acad Sci U S A (2011) 1.87
Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control (2010) 1.77
Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet (2007) 1.72
The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem (2009) 1.71
LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci (2009) 1.64
Regulation of p53 localization. Eur J Biochem (2001) 1.57
The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells. Mol Cell Biol (1996) 1.53
A bipartite nuclear localization signal is required for p53 nuclear import regulated by a carboxyl-terminal domain. J Biol Chem (1999) 1.48
p53 C-terminal phosphorylation by CHK1 and CHK2 participates in the regulation of DNA-damage-induced C-terminal acetylation. Mol Biol Cell (2005) 1.46
Parkinson's disease and cancer: two wars, one front. Nat Rev Cancer (2011) 1.45
Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat Cell Biol (2009) 1.41
Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart. Nat Commun (2013) 1.36
The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro. Mol Cell Biol (1997) 1.34
Dynamics in the p53-Mdm2 ubiquitination pathway. Cell Cycle (2004) 1.33
GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet (2012) 1.29
p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci Lett (2006) 1.24
Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One (2012) 1.21
LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity. Exp Cell Res (2009) 1.21
Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. Hum Mutat (2011) 1.16
SOX4 overexpression regulates the p53-mediated apoptosis in hepatocellular carcinoma: clinical implication and functional analysis in vitro. Carcinogenesis (2010) 1.13
ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2. J Neurosci (2012) 1.13
p53 mediates DNA damaging drug-induced apoptosis through a caspase-9-dependent pathway in SH-SY5Y neuroblastoma cells. Mol Cancer Ther (2002) 1.11
Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated. Clin Cancer Res (1999) 1.09
Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proc Natl Acad Sci U S A (2011) 1.05
Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells. J Biol Chem (2010) 1.02
Mortality and cancer incidence in patients with Parkinson's disease. J Neurol (2000) 1.01
LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations. FEBS Lett (2011) 1.00
p53 in neurodegenerative diseases and brain cancers. Pharmacol Ther (2013) 0.98
Oxidized DJ-1 inhibits p53 by sequestering p53 from promoters in a DNA-binding affinity-dependent manner. Mol Cell Biol (2012) 0.97
Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. JAMA Neurol (2015) 0.97
Activation of p53 signaling initiates apoptotic death in a cellular model of Parkinson's disease. Apoptosis (2006) 0.97
Apoptosis in Parkinson's disease: is p53 the missing link between genetic and sporadic Parkinsonism? Cell Signal (2010) 0.97
Phosphorylation of LRRK2: from kinase to substrate. Biochem Soc Trans (2012) 0.96
Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif. PLoS One (2010) 0.96
Posttranslational phosphorylation of mutant p53 protein in tumor development. Med Mol Morphol (2006) 0.96
The in vitro phosphorylation of p53 by calcium-dependent protein kinase C--characterization of a protein-kinase-C-binding site on p53. Eur J Biochem (1997) 0.95
LRRK2 phosphorylates novel tau epitopes and promotes tauopathy. Acta Neuropathol (2013) 0.94
Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease. BMB Rep (2010) 0.93
Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation. Front Mol Neurosci (2014) 0.89
LRRK2 phosphorylates Snapin and inhibits interaction of Snapin with SNAP-25. Exp Mol Med (2013) 0.88
Cytoskeleton-associated proteins are enriched in human embryonic-stem cell-derived neuroectodermal spheres. Proteomics (2009) 0.87
S-Nitrosylation of parkin as a novel regulator of p53-mediated neuronal cell death in sporadic Parkinson's disease. Mol Neurodegener (2013) 0.87
Threonine 56 phosphorylation of Bcl-2 is required for LRRK2 G2019S-induced mitochondrial depolarization and autophagy. Biochim Biophys Acta (2014) 0.87
Extensive post-translational modification of active and inactivated forms of endogenous p53. Mol Cell Proteomics (2013) 0.86
The LRRK2 inhibitor GSK2578215A induces protective autophagy in SH-SY5Y cells: involvement of Drp-1-mediated mitochondrial fission and mitochondrial-derived ROS signaling. Cell Death Dis (2014) 0.86
Regulation of the p53 protein by protein kinase C alpha and protein kinase C zeta. Biochem Biophys Res Commun (1998) 0.85
Differential subcellular p53 localization and function in N- and S-type neuroblastoma cell lines. Cell Growth Differ (1998) 0.84
p38(MAPK)/p53-Mediated Bax induction contributes to neurons degeneration in rotenone-induced cellular and rat models of Parkinson's disease. Neurochem Int (2013) 0.82
An early endosome regulator, Rab5b, is an LRRK2 kinase substrate. J Biochem (2015) 0.81
Repression of rRNA transcription by PARIS contributes to Parkinson's disease. Neurobiol Dis (2014) 0.79
Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein. Bioorg Med Chem Lett (2011) 0.79
Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology. Biochem Soc Trans (2012) 0.79
PINK1 positively regulates HDAC3 to suppress dopaminergic neuronal cell death. Hum Mol Genet (2014) 0.78
Dexamethasone induces the expression of LRRK2 and α-synuclein, two genes that when mutated cause Parkinson's disease in an autosomal dominant manner. BMB Rep (2013) 0.78
LRRK2-G2019S mutation is not associated with an increased cancer risk: a kin-cohort study. Mov Disord (2014) 0.76